Sharekhan

Anuh Pharma Ltd

Tue 17/02/2026,15:59:50 | NSE : ANUHPHR

₹ 81.720.64 (0.79%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 80.75

Previous Close

₹ 81.08

Volume

25984

Mkt Cap ( Rs. Cr)

₹819.03

High

₹ 83.20

Low

₹ 80.75

52 Week High

₹ 114.90

52 Week Low

₹ 69.27

Book Value Per Share

₹ 32.62

Dividend Yield

1.85

Face Value

₹ 5.00

What’s Your Call?

Collective community sentiment on Anuh Pharma Ltd

Your Vote -

Buy

85.71%

Hold

9.52%

Sell

4.76%

85.71%

21 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Anuh Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Anuh Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    13 Feb 2026, 4:26PM Investor Presentation for Q3 FY 2025-26
  • Anuh Pharma - Investor Presentation

    13 Feb 2026, 4:22PM Anuh Pharma Limited has informed the Exchange about Investor Presentation
  • Anuh Pharma - Copy of Newspaper Publication

    8 Feb 2026, 5:06PM Anuh Pharma Limited has informed the Exchange about Copy of Newspaper Publication of the Un-Audited financial results for the Quarter ended 31st Decem
  • Anuh Pharma - Announcement Under Regulation 30 (LODR) - Completion Of United States Food And Drug Administration (USFDA) Insp

    6 Feb 2026, 7:47PM Completion of United States Food and Drug Administration (USFDA) Inspection with no Form 483 observations issued.
  • Anuh Pharma - Updates

    6 Feb 2026, 7:40PM Anuh Pharma Limited has informed the Exchange regarding Completion of United States Food and Drug Administration (USFDA) inspection with no Form 483 o
  • Anuh Pharma - Announcement Under Regulation 30 (LODR) - Granting Authorization To Key Managerial Personnel For Determination

    6 Feb 2026, 7:30PM Granting Authorization to Key Managerial Personnel for determination of materiality of events/ information under Regulation 30 (5) of SEBI (LODR) Regu
  • Anuh Pharma - Updates

    6 Feb 2026, 7:23PM Anuh Pharma Limited has informed the Exchange regarding Granting Authorization to Key Managerial Personnel for determination of materiality of events/
  • Anuh Pharma Q3 net profit up 30.08% at Rs 13.45 cr

    6 Feb 2026, 7:10PM The company reported standalone net profit of Rs 13.45 crore for the quarter ended December 31, 2025 as compared to Rs 10.34 crore in the same period
  • Anuh Pharma - Results-Financial Results For December 31, 2025

    6 Feb 2026, 7:03PM Unaudited Financial Results for the quarter ended 31st December, 2025
  • Anuh Pharma - Outcome of Board Meeting

    6 Feb 2026, 6:49PM Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
  • Anuh Pharma - Outcome of Board Meeting

    6 Feb 2026, 6:29PM Anuh Pharma Limited has informed the Exchange regarding the approval of Un-audited Financial Results for the quarter ended December 31, 2025 and Grant
  • Anuh Pharma - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 31

    2 Feb 2026, 3:51PM Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and appr
  • Anuh Pharma Ltd - Action(s) taken or orders passed

    21 Jan 2026, 3:44PM Anuh Pharma Limited has informed the Exchange about orders passed regarding Assessment Order received under Section 143(3) read with Section 263 and 1
  • Anuh Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    20 Jan 2026, 4:40PM As of December 2025, 71.82% is owned by Promoters and 28.18% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 71.80% and F
  • Anuh Pharma Ltd - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    12 Jan 2026, 3:42PM Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Anuh Pharma Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    12 Jan 2026, 3:33PM Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 202
  • Anuh Pharma Ltd - Trading Window

    25 Dec 2025, 2:27PM Anuh Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Anuh Pharma Ltd - Updates

    5 Dec 2025, 11:43AM Anuh Pharma Limited has informed the Exchange regarding Approval from EDQM for CEP of Sulfadimethoxine.
  • Anuh Pharma Ltd - Announcement Under Regulation 30 (LODR) - Updates

    5 Dec 2025, 11:32AM Approval from EDQM for CEP of Sulfadimethoxine.
  • Anuh Pharma gets nod from WHO

    29 Sep 2020 , 10:28AM Anuh Pharma Ltd receives approval from WHO for Pyrimcthamine API

Key fundamentals

Evaluate the intrinsic value of Anuh Pharma Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 336.5229 293.2313 241.2214 216.8838 204.2412
Liabilities 336.5229 293.2313 241.2214 216.8838 204.2412
Equity 25.056 25.056 25.056 25.056 25.056
Gross Profit 60.9087 75.1491 51.2745 46.8455 44.5835
Net Profit 47.3519 60.0575 36.1796 30.5613 28.4363
Cash From Operating Activities 37.1248 12.9251 53.9016 28.8637 -18.7347
NPM(%) 7.15 9.28 6.85 6.27 6.58
Revenue 661.5149 647.0043 527.486 486.6462 431.9601
Expenses 600.6062 571.8552 476.2115 439.8007 387.3766
ROE(%) 14.48 18.37 11.06 9.34 8.69

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
14 Aug 2025 1.5 30 1.84 207.39

Peers

Other companies within the same industry or sector that are comparable to Anuh Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 734.25 -0.23 43.60 46.24 301.39 0.68
Lotus Eye Hospital and Institute Ltd 124.00 4.44 400.00 168.49 3.55 0.00
Vaishali Pharma Ltd 7.92 -1.74 0.00 1057.00 3.13 0.00
Astec Lifesciences Ltd 642.60 3.12 0.00 158.89 -604.77 0.00

Company Info

1961 - Anuh Pharma Ltd was incorporated. 2006 - In early January, the promoters sold off nearly 14.9% of their stake in the company. -Anuh Pharma has given the Bonus in the Ratio of 1:1 -Company has splits its Face value of Shares from Rs 10 to Rs 5 2010 -Anuh Pharma has given the Bonus in the Ratio of 2:1 2011 -Anuh Pharma has recommended a Dividend of Rs. 5.00 per share of face value of Rs. 5.00. 2012 -Anuh Pharma Ltd has entered into a Memorandum of Understanding with M/s. Invent Pharma Pvt. Ltd., to acquire all fixed assets of their Research & Development Laboratory. -Anuh Pharma has recommended a dividend of Rs. 5.50 per equity share of face value of Rs. 5.00. 2013 -Anuh Pharma has recommended a dividend of Rs. 6.00 per equity share of face value of Rs. 5.00. 2014 -Anuh Pharma Ltd have received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of Companys Erythromycin products namely Erythromycin Estolate, Erythromycin Ethyl Succinate & Erythromycin Stearate. -Anuh Pharma has recommended a Final Dividend of Rs. 6.50 (130%) per share. 2015 -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 2:1. 2016 -Anu Pharma Ltd has received EUGMP Certificate granted by ANSM - France. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1. 2025-The Company has issued Bonus Shares in the Ratio of 1:1.

1961 - Anuh Pharma Ltd was incorporated. 2006 - In early January, the promoters sold off nearly 14.9% of their stake in the company. -Anuh Pharma has given the Bonus in the Ratio of 1:1 -Company has splits its Face value of Shares from Rs 10 to Rs 5 2010 -Anuh Pharma has given the Bonus in the Ratio of 2:1 2011 -Anuh Pharma has recommended a Dividend of Rs. 5.00 per share of face value of Rs. 5.00. 2012 -Anuh Pharma Ltd has entered into a Memorandum of Understanding with M/s. Invent Pharma Pvt. Ltd., to acquire all fixed assets of their Research & Development Laboratory. -Anuh Pharma has recommended a dividend of Rs. 5.50 per equity share of face value of Rs. 5.00. 2013 -Anuh Pharma has recommended a dividend of Rs. 6.00 per equity share of face value of Rs. 5.00. 2014 -Anuh Pharma Ltd have received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of Companys Erythromycin products namely Erythromycin Estolate, Erythromycin Ethyl Succinate & Erythromycin Stearate. -Anuh Pharma has recommended a Final Dividend of Rs. 6.50 (130%) per share. 2015 -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 2:1. 2016 -Anu Pharma Ltd has received EUGMP Certificate granted by ANSM - France. 2020 -The Company has issued Bonus Shares in the Ratio of 1:1. 2025-The Company has issued Bonus Shares in the Ratio of 1:1.

Read More

Parent Organisation

Anuh Pharma Ltd.

Founded

19/02/1960

Managing Director

Mr.Ritesh B Shah

NSE Symbol

ANUHPHREQ

FAQ

The current price of Anuh Pharma Ltd is ₹ 81.72.

The 52-week high for Anuh Pharma Ltd is ₹ 83.20 and the 52-week low is ₹ 80.75.

The market capitalization of Anuh Pharma Ltd is currently ₹ 819.03. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Anuh Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Anuh Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Anuh Pharma Ltd shares.

The CEO of Anuh Pharma Ltd is Mr.Ritesh B Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT